Sermorelin, 2mg
Price range: $25.95 through $259.90
Sermorelin (GRF 1–29) is a synthetic 29-amino-acid fragment of endogenous GHRH(1–44), representing the minimal active sequence required for full GHRHR agonist activity. GHRHR binding activates Gsα-coupled adenylyl cyclase, stimulating pulsatile GH release from anterior pituitary somatotrophs. Research applications… CAS: 114466-38-5 | Formula: C151H250N44O44S | Content: 2 mg per vial | Research use only | Third-party lab tested.
Buy Sermorelin, 2mg – Swiss Chems USA
Sermorelin, 2mg — Research Overview
Sermorelin (GRF 1–29) is a synthetic 29-amino-acid fragment of endogenous GHRH(1–44), representing the minimal active sequence required for full GHRHR agonist activity. GHRHR binding activates Gsα-coupled adenylyl cyclase, stimulating pulsatile GH release from anterior pituitary somatotrophs. Research applications include GHRHR pharmacology, somatotropic axis characterisation, and comparative GHRH analogue potency studies.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Intended use: This material is supplied for laboratory and in-vitro research only. It is not a drug, food, or cosmetic and is not intended for human or animal consumption.
Sermorelin, 2mg Chemical Properties
| Property | Specification |
|---|---|
| Chemical Formula | C151H250N44O44S |
| Synonyms | UNII-89243S03TE, 89243S03TE, Sermoreline, Sermorelinum, Growth Hormone Releasing Factor (GRF) (1-29) amide |
| Molar Mass | 3417.9 g/mol |
| CAS Number | 114466-38-5 |
| PubChem CID | 16132412 |
| Total Compound Content | 2 mg per vial |
| Shelf Life | 36 months |
Sermorelin, 2mg Research Applications
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal region of growth hormone-releasing hormone (GHRH). The first 29 amino acid residues contain the structural elements required for high-affinity interaction with the growth hormone-releasing hormone receptor (GHRHR), making Sermorelin a widely utilized reference compound in GHRHR pharmacology research. Receptor activation initiates Gsα-coupled signaling, resulting in intracellular cAMP generation, protein kinase A (PKA) activation, and downstream signal transduction events associated with GHRHR-mediated pathway activity. Due to its well-characterized structure and receptor interaction profile, Sermorelin has been extensively employed in investigations of ligand-receptor binding dynamics, receptor activation mechanisms, peptide structure-activity relationships, and comparative analyses of GHRH analogues. Additional research has examined its pharmacokinetic properties, receptor engagement characteristics, and signaling pathway activation relative to modified GHRHR agonists. Research applications include GHRHR pharmacology, receptor signaling studies, peptide engineering investigations, ligand optimization research, and mechanistic evaluation of GHRHR-mediated signal transduction. Supplied as a lyophilized preparation (2 mg/vial). Independently third-party HPLC-tested; COA available per batch.
Sermorelin, 2mg Lab Results & Certificates of Analysis
Third-party analytical reports associated with this research compound:
Sermorelin, 2mg Frequently Asked Questions
What is the relationship between Sermorelin and endogenous GHRH?
Sermorelin is a synthetic 29-amino-acid fragment of the first 29 residues of endogenous human GHRH(1–44). Studies established that GHRH(1–29) retains full GHRHR agonist potency relative to the intact 44-residue peptide, as the N-terminal region contains the receptor-binding and activation domain. Sermorelin is therefore functionally equivalent to GHRH in terms of GHRHR pharmacology, though the shorter length confers a slightly shorter plasma half-life.
How does Sermorelin’s half-life compare to other GHRH analogues used in research?
Sermorelin has a plasma half-life of approximately 10–20 minutes due to DPP-IV cleavage vulnerability. Tesamorelin (N-terminal trans-3-hexenoic acid modification) extends this to approximately 26–38 minutes. CJC-1295 without DAC (GRF 1–29) uses substitutions at positions 2, 8, 15, and 27 to provide DPP-IV resistance (t½ ~30 min), and CJC-1295 with DAC covalently binds albumin (t½ ~7–8 days). Sermorelin’s shorter half-life makes it appropriate for studies requiring discrete, acute GH pulse induction.
Why is Sermorelin considered a reference compound in GHRHR research?
Sermorelin possesses one of the most extensively characterized pharmacological profiles among GHRHR agonists, with well-documented receptor binding properties, signaling activity, and ligand-receptor interaction data. Its defined structure, established receptor affinity, and thoroughly studied activation mechanisms have made it a widely used reference compound for investigations involving GHRHR pharmacology, receptor activation kinetics, structure-activity relationships, and comparative analyses of GHRH analogues. As a result, Sermorelin is frequently utilized as a benchmark molecule in studies examining receptor signaling, ligand optimization, and GHRHR-mediated signal transduction.
Research Use Disclaimer
All product information is provided for educational and laboratory research reference only. Any form of introduction into humans or animals is prohibited. Handle only in licensed research settings in accordance with applicable laws and institutional protocols.
| Weight | 1 lbs |
|---|---|
| Sermorelin 2Mg |
KIT (10 vials) ,Vial |
Related products
CJC-1295 without DAC 2 mg
Price range: $42.95 through $429.50
Epitalon 10 mg
Price range: $23.16 through $231.60
Follistatin-344 1mg
Price range: $139.99 through $1,399.90
Gonadorelin 2mg
Price range: $24.95 through $249.50
MGF without PEG 2mg
Price range: $29.99 through $299.90
PEG MGF 2mg
Price range: $47.95 through $479.50
Reviews
There are no reviews yet.